Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol and Radiation in Soft Tissue Sarcoma
NCT06670976Phase 1Withdrawn
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- May 2026
- Primary completion
- Nov 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of propranolol in soft tissue sarcoma (STS), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Incidence of adverse events. Planned start May 2026; status: withdrawn.
02
Drugs
propranolol
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06670976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06670976.